NDAORALCAPSULE
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
LYRICA (pregabalin) by Teva is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2004.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA (pregabalin) is an oral small-molecule anticonvulsant that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It is indicated for neuropathic pain, fibromyalgia, and postherpetic neuralgia by reducing calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord. The drug works through modulation of descending pain pathways rather than direct GABA or opioid receptor binding.
$0.072BPart D
LOE ApproachingProduct is approaching loss of exclusivity with moderate Medicare utilization; commercial teams should anticipate generics competition and defend market share against erosion.
Mechanism of Action
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.